AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PPARGC1A) is a transcriptional co-activator with a central role in energy expenditure and glucose metabolism. Several studies have suggested that the common PPARGC1A polymorphism Gly482Ser may be associated with risk of type 2 diabetes, with conflicting results. To clarify the role of Gly482Ser in type 2 diabetes and related human metabolic phenotypes we genotyped this polymorphism in a case-control study and performed a meta-analysis of relevant published data. MATERIALS AND METHODS: Gly482Ser was genotyped in a type 2 diabetes case-control study (N=1,096) using MassArray technology. A literature search revealed publications that examined Gly482Ser for association with type 2 diabetes and related metabolic phenotypes. Meta-analysis of the current study and relevant published data was undertaken. RESULTS: In the pooled meta-analysis, including data from this study and seven published reports (3,718 cases, 4,818 controls), there was evidence of between-study heterogeneity (p<0.1). In the fixed-effects meta-analysis, the pooled odds ratio for risk of type 2 diabetes per Ser482 allele was 1.07 (95% CI 1.00-1.15, p=0.044). Elimination of one of the studies from the meta-analysis gave a summary odds ratio of 1.11 (95% CI 1.04-1.20, p=0.004), with no between-study heterogeneity (p=0.475). For quantitative metabolic traits in normoglycaemic subjects, we also found significant between-study heterogeneity. However, no significant association was observed between Gly482Ser and BMI, fasting glucose or fasting insulin. CONCLUSIONS/ INTERPRETATION: This meta-analysis of data from the current and published studies supports a modest role for the Gly482Ser PPARGC1A variant in type 2 diabetes risk.
AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PPARGC1A) is a transcriptional co-activator with a central role in energy expenditure and glucose metabolism. Several studies have suggested that the common PPARGC1A polymorphism Gly482Ser may be associated with risk of type 2 diabetes, with conflicting results. To clarify the role of Gly482Ser in type 2 diabetes and related human metabolic phenotypes we genotyped this polymorphism in a case-control study and performed a meta-analysis of relevant published data. MATERIALS AND METHODS: Gly482Ser was genotyped in a type 2 diabetes case-control study (N=1,096) using MassArray technology. A literature search revealed publications that examined Gly482Ser for association with type 2 diabetes and related metabolic phenotypes. Meta-analysis of the current study and relevant published data was undertaken. RESULTS: In the pooled meta-analysis, including data from this study and seven published reports (3,718 cases, 4,818 controls), there was evidence of between-study heterogeneity (p<0.1). In the fixed-effects meta-analysis, the pooled odds ratio for risk of type 2 diabetes per Ser482 allele was 1.07 (95% CI 1.00-1.15, p=0.044). Elimination of one of the studies from the meta-analysis gave a summary odds ratio of 1.11 (95% CI 1.04-1.20, p=0.004), with no between-study heterogeneity (p=0.475). For quantitative metabolic traits in normoglycaemic subjects, we also found significant between-study heterogeneity. However, no significant association was observed between Gly482Ser and BMI, fasting glucose or fasting insulin. CONCLUSIONS/ INTERPRETATION: This meta-analysis of data from the current and published studies supports a modest role for the Gly482Ser PPARGC1A variant in type 2 diabetes risk.
Authors: Harald Esterbauer; Hannes Oberkofler; Veronika Linnemayr; Bernhard Iglseder; Margot Hedegger; Peter Wolfsgruber; Bernhard Paulweber; Gerd Fastner; Franz Krempler; Wolfgang Patsch Journal: Diabetes Date: 2002-04 Impact factor: 9.461
Authors: J C Yoon; P Puigserver; G Chen; J Donovan; Z Wu; J Rhee; G Adelmant; J Stafford; C R Kahn; D K Granner; C B Newgard; B M Spiegelman Journal: Nature Date: 2001-09-13 Impact factor: 49.962
Authors: Alejandro Lucia; Félix Gómez-Gallego; Inês Barroso; Manuel Rabadán; Fernando Bandrés; Alejandro F San Juan; José L Chicharro; Ulf Ekelund; Soren Brage; Conrad P Earnest; Nicholas J Wareham; Paul W Franks Journal: J Appl Physiol (1985) Date: 2005-02-10
Authors: Anna L Gloyn; Michael N Weedon; Katharine R Owen; Martina J Turner; Bridget A Knight; Graham Hitman; Mark Walker; Jonathan C Levy; Mike Sampson; Stephanie Halford; Mark I McCarthy; Andrew T Hattersley; Timothy M Frayling Journal: Diabetes Date: 2003-02 Impact factor: 9.461
Authors: Inês Barroso; Jian'an Luan; Rita P S Middelberg; Anne-Helen Harding; Paul W Franks; Rupert W Jakes; D Clayton; Alan J Schafer; Stephen O'Rahilly; Nicholas J Wareham Journal: PLoS Biol Date: 2003-10-13 Impact factor: 8.029
Authors: Erwin Reiling; Jana V van Vliet-Ostaptchouk; Esther van 't Riet; Timon W van Haeften; Pascal A Arp; Torben Hansen; Dennis Kremer; Marlous J Groenewoud; Els C van Hove; Johannes A Romijn; Jan W A Smit; Giel Nijpels; Robert J Heine; André G Uitterlinden; Oluf Pedersen; P Eline Slagboom; Johannes A Maassen; Marten H Hofker; Leen M 't Hart; Jacqueline M Dekker Journal: Eur J Hum Genet Date: 2009-02-11 Impact factor: 4.246
Authors: M Sjögren; V Lyssenko; A Jonsson; G Berglund; P Nilsson; L Groop; M Orho-Melander Journal: Diabetologia Date: 2008-10-14 Impact factor: 10.122
Authors: E C Brito; K S Vimaleswaran; S Brage; L B Andersen; L B Sardinha; N J Wareham; U Ekelund; R J F Loos; P W Franks Journal: Diabetologia Date: 2009-01-29 Impact factor: 10.122
Authors: M Gielen; M S Westerterp-Plantenga; F G Bouwman; A M C P Joosen; R Vlietinck; C Derom; M P Zeegers; E C M Mariman; K R Westerterp Journal: Genes Nutr Date: 2014-07-05 Impact factor: 5.523